These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31262589)

  • 1. Defining the multiplicity and time of infection for the production of Zaire Ebola virus-like particles in the insect cell-baculovirus expression system.
    Pastor AR; González-Domínguez G; Díaz-Salinas MA; Ramírez OT; Palomares LA
    Vaccine; 2019 Nov; 37(47):6962-6969. PubMed ID: 31262589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
    Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 5. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies.
    Ye L; Lin J; Sun Y; Bennouna S; Lo M; Wu Q; Bu Z; Pulendran B; Compans RW; Yang C
    Virology; 2006 Aug; 351(2):260-70. PubMed ID: 16678231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays.
    Kamata T; Natesan M; Warfield K; Aman MJ; Ulrich RG
    Clin Vaccine Immunol; 2014 Dec; 21(12):1605-12. PubMed ID: 25230936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
    Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
    Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
    Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG
    Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
    Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
    Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology.
    Johnson RF; Bell P; Harty RN
    Virol J; 2006 May; 3():31. PubMed ID: 16719918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
    Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against lethal challenge by Ebola virus-like particles produced in insect cells.
    Sun Y; Carrion R; Ye L; Wen Z; Ro YT; Brasky K; Ticer AE; Schwegler EE; Patterson JL; Compans RW; Yang C
    Virology; 2009 Jan; 383(1):12-21. PubMed ID: 18986663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein.
    Kumar D; Gauthami S; Uma M; Nagalekshmi K; Rao PP; Basu A; Ella KM; Hegde NR
    Viral Immunol; 2018 Sep; 31(7):500-512. PubMed ID: 30095362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.
    Lehrer AT; Wong TS; Lieberman MM; Humphreys T; Clements DE; Bakken RR; Hart MK; Pratt WD; Dye JM
    Vaccine; 2018 May; 36(22):3090-3100. PubMed ID: 28216187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins.
    Groen J; van den Hoogen BG; Burghoorn-Maas CP; Fooks AR; Burton J; Clegg CJ; Zeller H; Osterhaus AD
    Microbes Infect; 2003 Apr; 5(5):379-85. PubMed ID: 12737993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus.
    Becquart P; Mahlakõiv T; Nkoghe D; Leroy EM
    PLoS One; 2014; 9(6):e96360. PubMed ID: 24914933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles.
    Licata JM; Johnson RF; Han Z; Harty RN
    J Virol; 2004 Jul; 78(14):7344-51. PubMed ID: 15220407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.